Equity Profile

ZBH

Zimmer Biomet Holdings, Inc.

Health CareHealth Care Equipment$15.9B

Apr28Tue

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:30 AM EDT

Zimmer Biomet Beats on EPS, Stock Up 1.46%

Metric	Actual	Expected	Surprise
EPS	$2.09	$1.86	+12.55%
Revenue	N/A	$2.1B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Zimmer Biomet Beats on EPS, Stock Up 1.46%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$2.09	$1.86	+12.55%
Revenue	N/A	$2.1B	N/A

Management Commentary

Tone: Cautiously Optimistic

Overall, management expressed cautious optimism about future growth driven by product innovation. They acknowledged some supply chain challenges but are committed to addressing them.

Management highlighted strong demand in key product categories.

They noted ongoing challenges in supply chain but remain focused on operational improvements.

What It Means

Zimmer Biomet's strong EPS performance indicates better-than-expected profitability, which likely contributed to the stock's 1.46% increase. However, the lack of revenue data and guidance leaves some uncertainty about future performance. Investors may be encouraged by management's focus on product demand and operational improvements despite supply chain issues.

Company Snapshot

Zimmer Biomet Holdings, Inc. is a leading company in the health care sector, specializing in medical devices and equipment for musculoskeletal health....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and is closely watched by investors.

$1.86

Revenue

Total revenue gives insight into the company's overall sales performance and market demand for its products.

$2.1B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Zimmer Biomet Holdings, Inc. is a leading company in the health care sector, specializing in medical devices and equipment for musculoskeletal health. With a market cap of $18 billion, it plays a crucial role in providing innovative solutions for orthopedic surgeries and rehabilitation, which is increasingly important as the global population ages and requires more medical care.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+2.87%

Avg Stock Reaction

-3.79%

Last Quarter Recap

In Q4 2025, Zimmer Biomet reported an EPS of $2.42, slightly beating expectations. The stock reacted positively, gaining 1.86% the following day.

Management Promises & Guidance

Continued focus on innovation in orthopedic solutions.
Commitment to improving operational efficiency.
Plans to expand market presence in emerging regions.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Zimmer Biomet's upcoming earnings, expecting solid performance in both EPS and revenue. The company has a strong history of beating earnings estimates, which could lead to positive market reactions.

Bull Case

If Zimmer Biomet exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products, leading to a significant stock price increase.

Bear Case

Conversely, if the company misses its EPS or revenue targets, it may raise concerns about market demand and operational challenges, resulting in a negative stock reaction.

Key Metrics to Watch

EPS

$1.86

Earnings per share is a key indicator of the company's profitability and is closely watched by investors.

Revenue

$2.1B

Total revenue gives insight into the company's overall sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $1.86?

A beat on EPS could reinforce confidence in the company's profitability and growth potential, positively impacting the stock.

What revenue figures will the company report, especially in light of market demand?

Revenue performance is crucial for understanding sales trends and market acceptance of Zimmer Biomet's products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of emerging market growth on Zimmer Biomet's revenue, which could lead to stronger-than-expected results.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with an 88% beat rate over the last eight quarters.

Recent trends in the orthopedic market suggest increasing demand for innovative solutions, which could boost sales.

The options market is pricing a larger move than historical averages, indicating potential volatility that the consensus may not fully account for.

Key Risk

If revenue growth significantly outpaces expectations due to strong demand in emerging markets, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect the company's ability to navigate market challenges and capitalize on growth opportunities.

Bull Confirmed If

An EPS of $1.90 or higher, along with revenue exceeding $2.1B, would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $1.84 or revenue falling short of $2.0B would indicate potential challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±7.32%

Historical Avg

±7.7%

In line with history

The options market is pricing in a significant potential move in either direction, indicating uncertainty about the upcoming earnings report.

Options are pricing ±7.5% while ZBH has averaged ±7.7% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

23.6%

Calls (23K)P/C Ratio: 0.58Puts (13K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zimmer Biomet beats expectations, history suggests a potential stock increase of around 3.1%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss its targets, history indicates a potential drop of about 5.7%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in orthopedic solutions.
2Insights into market demand trends, particularly in emerging regions.
3Management's commentary on operational efficiency and cost management.
4Guidance on future revenue expectations and growth strategies.
5Responses to questions about competitive pressures in the health care equipment sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Zimmer Biomet Holdings, Inc. is a leading company in the health care sector, specializing in medical devices and equipment for musculoskeletal health....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and is closely watched by investors.

$1.86

Revenue

Total revenue gives insight into the company's overall sales performance and market demand for its products.

$2.1B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+2.87%

Avg Stock Reaction

-3.79%

Last Quarter Recap

In Q4 2025, Zimmer Biomet reported an EPS of $2.42, slightly beating expectations. The stock reacted positively, gaining 1.86% the following day.

Management Promises & Guidance

Continued focus on innovation in orthopedic solutions.
Commitment to improving operational efficiency.
Plans to expand market presence in emerging regions.

Expectations

Wall Street Expectations

Bull Case

If Zimmer Biomet exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products, leading to a significant stock price increase.

Bear Case

Conversely, if the company misses its EPS or revenue targets, it may raise concerns about market demand and operational challenges, resulting in a negative stock reaction.

Key Metrics to Watch

EPS

$1.86

Earnings per share is a key indicator of the company's profitability and is closely watched by investors.

Revenue

$2.1B

Total revenue gives insight into the company's overall sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $1.86?

A beat on EPS could reinforce confidence in the company's profitability and growth potential, positively impacting the stock.

What revenue figures will the company report, especially in light of market demand?

Revenue performance is crucial for understanding sales trends and market acceptance of Zimmer Biomet's products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of emerging market growth on Zimmer Biomet's revenue, which could lead to stronger-than-expected results.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with an 88% beat rate over the last eight quarters.

Recent trends in the orthopedic market suggest increasing demand for innovative solutions, which could boost sales.

The options market is pricing a larger move than historical averages, indicating potential volatility that the consensus may not fully account for.

Key Risk

If revenue growth significantly outpaces expectations due to strong demand in emerging markets, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect the company's ability to navigate market challenges and capitalize on growth opportunities.

Bull Confirmed If

An EPS of $1.90 or higher, along with revenue exceeding $2.1B, would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $1.84 or revenue falling short of $2.0B would indicate potential challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±7.32%

Historical Avg

±7.7%

In line with history

The options market is pricing in a significant potential move in either direction, indicating uncertainty about the upcoming earnings report.

Options are pricing ±7.5% while ZBH has averaged ±7.7% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

23.6%

Calls (23K)P/C Ratio: 0.58Puts (13K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zimmer Biomet beats expectations, history suggests a potential stock increase of around 3.1%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss its targets, history indicates a potential drop of about 5.7%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in orthopedic solutions.
2Insights into market demand trends, particularly in emerging regions.
3Management's commentary on operational efficiency and cost management.
4Guidance on future revenue expectations and growth strategies.
5Responses to questions about competitive pressures in the health care equipment sector.